Quadria Capital, a leading healthcare-focused private equity firm, has finalized its third fund with a total commitment of $1.07 billion, significantly surpassing its original target of $800 million. The fund includes $954 million in primary commitments and $114 million in co-investment capital, with an additional $300 million expected during the investment phase—bringing total deployment capacity to around $1.3 billion.

This fund marks the largest healthcare-specific private equity vehicle in South and Southeast Asia, growing nearly 60% larger than Quadria’s $600 million fund from 2020. The firm plans to back around ten companies, focusing on India and Southeast Asia across key sectors such as specialty hospitals, diagnostics, MedTech, and pharmaceutical manufacturing.

India remains a strategic focal point, given its low per capita healthcare spending and high out-of-pocket expenses. Quadria aims to invest in scalable, cost-effective healthcare solutions while supporting impactful delivery models.

Despite a challenging global fundraising climate, Quadria received strong backing from sovereign wealth funds, asset managers, and institutional investors from North America, Europe, GCC countries, and India. This global support reflects investor confidence in the region’s healthcare potential and Quadria’s strategic vision.

Fund III has already deployed about 40% of its capital in companies like Aragen Life Sciences, NephroPlus, and Maxivision, with further deals expected soon in Southeast Asia.